GlassScriptPhysician profile
Scott A Rioch
NPI 1619947272
$16,481.09
in general payments reported to CMS, 2019-2025
55 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,753 · 2020: $2,070 · 2021: $2,622 · 2022: $2,206 · 2023: $2,522 · 2024: $2,528 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,824 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,823.70 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,410.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,286.58 | 2021-2025 | Vraylar, Linzess, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,152.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,051.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $920.47 | 2019-2025 | |
| Amgen INC. | $887.38 | 2019-2025 | Evenity, Otezla, Prolia |
| Lilly USA, LLC | $776.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $715.22 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $669.27 | 2019-2025 | Verquvo, Steglatro |
| Amarin Pharma, INC. | $382.56 | 2019-2022 | |
| Esperion Therapeutics, INC. | $378.13 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $376.22 | 2019-2024 | Trintellix |
| Abbott Laboratories | $293.63 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $268.07 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $260.59 | 2022-2025 | Rexulti |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rioch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.